{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:25:24Z","timestamp":1790641524934,"version":"4.1.0"},"reference-count":60,"publisher":"The Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>X-linked adrenoleukodystrophy (X-ALD) is a rare, genetic disorder characterized by adrenal insufficiency and central nervous system (CNS) demyelination. All patients with X-ALD have the biochemical abnormality of elevated blood and tissue levels of very long chain fatty acids (VLCFAs), saturated fatty acids with 24 to 26 carbons. X-ALD results from loss of function mutations in the gene encoding the peroxisomal transporter ABCD1, which is responsible for uptake of VLCFAs into peroxisomes for degradation by oxidation. One proposed therapeutic strategy for genetic complementation of ABCD1 is pharmacologic upregulation of ABCD2, a gene encoding a homologous peroxisomal transporter. Here, we show that thyroid hormone or sobetirome, a clinical-stage selective thyroid hormone receptor agonist, increases cerebral Abcd2 and lowers VLCFAs in blood, peripheral organs, and brains of mice with defective Abcd1. These results support an approach to treating X-ALD that involves a thyromimetic agent that reactivates VLCFA disposal both in the periphery and the CNS.<\/jats:p>","DOI":"10.1210\/en.2016-1842","type":"journal-article","created":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T11:25:38Z","timestamp":1492601138000},"page":"1328-1338","source":"Crossref","is-referenced-by-count":46,"title":["A Thyroid Hormone\u2013Based Strategy for Correcting the Biochemical Abnormality in X-Linked Adrenoleukodystrophy"],"prefix":"10.1210","volume":"158","author":[{"given":"Meredith D.","family":"Hartley","sequence":"first","affiliation":[{"name":"Department of Physiology and Pharmacology and Program in Chemical Biology, Oregon Health & Science University, Portland, Oregon 92739"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa L.","family":"Kirkemo","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology and Program in Chemical Biology, Oregon Health & Science University, Portland, Oregon 92739"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapasree","family":"Banerji","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology and Program in Chemical Biology, Oregon Health & Science University, Portland, Oregon 92739"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Scanlan","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology and Program in Chemical Biology, Oregon Health & Science University, Portland, Oregon 92739"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2017,2,14]]},"reference":[{"issue":"4","key":"2020071622335205200_B1","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1750-3639.2010.00390.x","article-title":"General aspects and neuropathology of X-linked adrenoleukodystrophy","volume":"20","author":"Ferrer","year":"2010","journal-title":"Brain Pathol"},{"issue":"3","key":"2020071622335205200_B2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/ncpneuro0421","article-title":"X-linked adrenoleukodystrophy","volume":"3","author":"Moser","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"issue":"10","key":"2020071622335205200_B3","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrendo.2016.90","article-title":"Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history","volume":"12","author":"Kemp","year":"2016","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2020071622335205200_B4","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1750-3639.2010.00391.x","article-title":"Biochemical aspects of X-linked adrenoleukodystrophy","volume":"20","author":"Kemp","year":"2010","journal-title":"Brain Pathol"},{"issue":"4","key":"2020071622335205200_B5","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1750-3639.2010.00392.x","article-title":"Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis","volume":"20","author":"Singh","year":"2010","journal-title":"Brain Pathol"},{"issue":"11","key":"2020071622335205200_B6","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/3242","article-title":"Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy","volume":"4","author":"Kemp","year":"1998","journal-title":"Nat Med"},{"issue":"1","key":"2020071622335205200_B7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12031-007-0041-4","article-title":"\u201cLorenzo\u2019s oil\u201d therapy for X-linked adrenoleukodystrophy: rationale and current assessment of efficacy","volume":"33","author":"Moser","year":"2007","journal-title":"J Mol Neurosci"},{"issue":"11","key":"2020071622335205200_B8","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM199309093291101","article-title":"A two-year trial of oleic and erucic acids (\u201cLorenzo\u2019s oil\u201d) as treatment for adrenomyeloneuropathy","volume":"329","author":"Aubourg","year":"1993","journal-title":"N Engl J Med"},{"issue":"7","key":"2020071622335205200_B9","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/archneur.62.7.1073","article-title":"Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo\u2019s oil","volume":"62","author":"Moser","year":"2005","journal-title":"Arch Neurol"},{"issue":"4","key":"2020071622335205200_B10","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1750-3639.2010.00393.x","article-title":"Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy","volume":"20","author":"Berger","year":"2010","journal-title":"Brain Pathol"},{"issue":"10","key":"2020071622335205200_B11","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.1074\/jbc.M110.211912","article-title":"Substrate specificity overlap and interaction between adrenoleukodystrophy protein (ALDP\/ABCD1) and adrenoleukodystrophy-related protein (ALDRP\/ABCD2)","volume":"286","author":"Genin","year":"2011","journal-title":"J Biol Chem"},{"issue":"2-3","key":"2020071622335205200_B12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0014-5793(99)00379-8","article-title":"Retroviral-mediated adrenoleukodystrophy-related gene transfer corrects very long chain fatty acid metabolism in adrenoleukodystrophy fibroblasts: implications for therapy","volume":"448","author":"Flavigny","year":"1999","journal-title":"FEBS Lett"},{"issue":"5","key":"2020071622335205200_B13","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/hmg\/8.5.907","article-title":"Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy","volume":"8","author":"Netik","year":"1999","journal-title":"Hum Mol Genet"},{"issue":"23","key":"2020071622335205200_B14","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1093\/hmg\/ddh323","article-title":"Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy","volume":"13","author":"Pujol","year":"2004","journal-title":"Hum Mol Genet"},{"issue":"12","key":"2020071622335205200_B15","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ejcb.2008.08.002","article-title":"Distinct modulatory roles for thyroid hormone receptors TRalpha and TRbeta in SREBP1-activated ABCD2 expression","volume":"87","author":"Weinhofer","year":"2008","journal-title":"Eur J Cell Biol"},{"issue":"6","key":"2020071622335205200_B16","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1124\/mol.63.6.1296","article-title":"Thyroid hormone induction of the adrenoleukodystrophy-related gene (ABCD2)","volume":"63","author":"Fourcade","year":"2003","journal-title":"Mol Pharmacol"},{"issue":"1-2","key":"2020071622335205200_B17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jsbmb.2009.04.006","article-title":"Induction of the adrenoleukodystrophy-related gene (ABCD2) by thyromimetics","volume":"116","author":"Genin","year":"2009","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"2020071622335205200_B18","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrd2830","article-title":"Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes","volume":"8","author":"Baxter","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"2020071622335205200_B19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10741-008-9122-x","article-title":"Sobetirome: a case history of bench-to-clinic drug discovery and development","volume":"15","author":"Scanlan","year":"2010","journal-title":"Heart Fail Rev"},{"issue":"9","key":"2020071622335205200_B20","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1210\/endo.141.9.7681","article-title":"The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity","volume":"141","author":"Trost","year":"2000","journal-title":"Endocrinology"},{"issue":"12","key":"2020071622335205200_B21","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1210\/en.2003-0633","article-title":"Differential effects of triiodothyronine and the thyroid hormone receptor beta-specific agonist GC-1 on thyroid hormone target genes in the b ain","volume":"144","author":"Manzano","year":"2003","journal-title":"Endocrinology"},{"issue":"35","key":"2020071622335205200_B22","doi-asserted-by":"crossref","first-page":"5946","DOI":"10.1016\/j.tet.2015.05.049","article-title":"New synthetic routes to thyroid hormone analogs: d6-sobetirome, 3H-sobetirome, and the antagonist NH-3","volume":"71","author":"Placzek","year":"2015","journal-title":"Tetrahedron"},{"issue":"6","key":"2020071622335205200_B23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1074-5521(98)90168-5","article-title":"A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor","volume":"5","author":"Chiellini","year":"1998","journal-title":"Chem Biol"},{"issue":"5","key":"2020071622335205200_B24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/(SICI)1097-4547(19971201)50:5<829::AID-JNR19>3.0.CO;2-W","article-title":"Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice","volume":"50","author":"Forss-Petter","year":"1997","journal-title":"J Neurosci Res"},{"issue":"11","key":"2020071622335205200_B25","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1210\/en.2012-1254","article-title":"Biosynthesis of 3-iodothyronamine (T1AM) is dependent on the sodium-iodide symporter and thyroperoxidase but does not involve extrathyroidal metabolism of T4","volume":"153","author":"Hackenmueller","year":"2012","journal-title":"Endocrinology"},{"key":"2020071622335205200_B26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-61779-111-6_2","article-title":"Dissection of Rodent Brain Regions","volume":"57","author":"Spijker","year":"2011","journal-title":"Neuroproteomics"},{"issue":"9","key":"2020071622335205200_B27","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT-PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"2020071622335205200_B28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ymgme.2009.03.010","article-title":"Newborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS\/MS) method","volume":"97","author":"Hubbard","year":"2009","journal-title":"Mol Genet Metab"},{"issue":"1-2","key":"2020071622335205200_B29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ymgme.2006.05.001","article-title":"Combined liquid chromatography-tandem mass spectrometry as an analytical method for high throughput screening for X-linked adrenoleukodystrophy and other peroxisomal disorders: preliminary findings","volume":"89","author":"Hubbard","year":"2006","journal-title":"Mol Genet Metab"},{"issue":"3","key":"2020071622335205200_B30","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2011.11.195","article-title":"Combined extraction of acyl carnitines and 26:0 lysophosphatidylcholine from dried blood spots: prospective newborn screening for X-linked adrenoleukodystrophy","volume":"105","author":"Sandlers","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2020071622335205200_B31","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1006\/mgme.2001.3170","article-title":"Quantitative determination of plasma c8-c26 total fatty acids for the biochemical diagnosis of nutritional and metabolic disorders","volume":"73","author":"Lagerstedt","year":"2001","journal-title":"Mol Genet Metab"},{"issue":"17","key":"2020071622335205200_B32","doi-asserted-by":"crossref","first-page":"9366","DOI":"10.1073\/pnas.94.17.9366","article-title":"A mouse model for X-linked adrenoleukodystrophy","volume":"94","author":"Lu","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2020071622335205200_B33","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1006\/bbrc.1997.6340","article-title":"Adrenoleukodystrophy protein-deficient mice represent abnormality of very long chain fatty acid metabolism","volume":"232","author":"Kobayashi","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"2020071622335205200_B34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1021635826032","article-title":"Turnover of myelin lipids in aging brain","volume":"28","author":"Ando","year":"2003","journal-title":"Neurochem Res"},{"issue":"1","key":"2020071622335205200_B35","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1089\/thy.2013.0109","article-title":"American Thyroid Association Guide to investigating thyroid hormone economy and action in rodent and cell models","volume":"24","author":"Bianco","year":"2014","journal-title":"Thyroid"},{"issue":"8","key":"2020071622335205200_B36","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.celrep.2015.10.022","article-title":"Pharmacological activation of thyroid hormone receptors elicits a functional conversion of white to brown fat","volume":"13","author":"Lin","year":"2015","journal-title":"Cell Reports"},{"issue":"22","key":"2020071622335205200_B37","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1016\/j.bmc.2016.09.038","article-title":"Sobetirome prodrug esters with enhanced blood-brain barrier permeability","volume":"24","author":"Placzek","year":"2016","journal-title":"Bioorg Med Chem"},{"issue":"7","key":"2020071622335205200_B38","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1248\/bpb.b13-00915","article-title":"In vivo evaluation of 1-benzyl-4-aminoindole-based thyroid hormone receptor \u03b2 agonists: importance of liver selectivity in drug discovery","volume":"37","author":"Takahashi","year":"2014","journal-title":"Biol Pharm Bull"},{"issue":"4","key":"2020071622335205200_B39","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1750-3639.2010.00394.x","article-title":"Hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy","volume":"20","author":"Cartier","year":"2010","journal-title":"Brain Pathol"},{"issue":"9231","key":"2020071622335205200_B40","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0140-6736(00)02629-5","article-title":"Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy","volume":"356","author":"Shapiro","year":"2000","journal-title":"Lancet"},{"issue":"12","key":"2020071622335205200_B41","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/hmg\/ddn066","article-title":"Toxic effects of X-linked adrenoleukodystrophy-associated, very long chain fatty acids on glial cells and neurons from rat hippocampus in culture","volume":"17","author":"Hein","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"2","key":"2020071622335205200_B42","doi-asserted-by":"crossref","first-page":"136","DOI":"10.14336\/AD.2015.0823","article-title":"Brain lipotoxicity of phytanic acid and very long-chain fatty acids. Harmful cellular\/mitochondrial activities in refsum disease and X-linked Adrenoleukodystrophy","volume":"7","author":"Sch\u00f6nfeld","year":"2016","journal-title":"Aging Dis"},{"issue":"3","key":"2020071622335205200_B43","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1172\/JCI118182","article-title":"Interactions of a very long chain fatty acid with model membranes and serum albumin. Implications for the pathogenesis of adrenoleukodystrophy","volume":"96","author":"Ho","year":"1995","journal-title":"J Clin Invest"},{"issue":"12","key":"2020071622335205200_B44","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/hmg\/ddn085","article-title":"Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy","volume":"17","author":"Fourcade","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"6","key":"2020071622335205200_B45","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.21391","article-title":"Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy?","volume":"63","author":"Eichler","year":"2008","journal-title":"Ann Neurol"},{"issue":"1","key":"2020071622335205200_B46","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/1531-8249(199901)45:1<100::AID-ART16>3.0.CO;2-U","article-title":"Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls","volume":"45","author":"Moser","year":"1999","journal-title":"Ann Neurol"},{"key":"2020071622335205200_B47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1750-1172-7-51","article-title":"X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management","volume":"7","author":"Engelen","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"2020071622335205200_B48","doi-asserted-by":"crossref","first-page":"e41013","DOI":"10.1371\/journal.pone.0041013","article-title":"Bezafibrate for X-linked adrenoleukodystrophy","volume":"7","author":"Engelen","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"2020071622335205200_B49","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s10545-012-9471-4","article-title":"Bezafibrate lowers very long-chain fatty acids in X-linked adrenoleukodystrophy fibroblasts by inhibiting fatty acid elongation","volume":"35","author":"Engelen","year":"2012","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"2020071622335205200_B50","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ymgme.2003.09.002","article-title":"Evaluation of the therapeutic potential of PPARalpha agonists for X-linked adrenoleukodystrophy","volume":"80","author":"Rampler","year":"2003","journal-title":"Mol Genet Metab"},{"issue":"10","key":"2020071622335205200_B51","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/hmg\/ddq082","article-title":"Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy","volume":"19","author":"Fourcade","year":"2010","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2020071622335205200_B52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1083\/jcb.200501036","article-title":"Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator","volume":"169","author":"Gondcaille","year":"2005","journal-title":"J Cell Biol"},{"key":"2020071622335205200_B53","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.bbalip.2013.01.004","article-title":"Caffeic acid phenethyl ester induces adrenoleukodystrophy (Abcd2) gene in human X-ALD fibroblasts and inhibits the proinflammatory response in Abcd1\/2 silenced mouse primary astrocytes","volume":"1831","author":"Singh","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"2020071622335205200_B54","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bbalip.2013.11.003","article-title":"LXR antagonists induce ABCD2 expression","volume":"1841","author":"Gondcaille","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"50","key":"2020071622335205200_B55","doi-asserted-by":"crossref","first-page":"41243","DOI":"10.1074\/jbc.M509450200","article-title":"Liver X receptor alpha interferes with SREBP1c-mediated Abcd2 expression. Novel cross-talk in gene regulation","volume":"280","author":"Weinhofer","year":"2005","journal-title":"J Biol Chem"},{"issue":"7","key":"2020071622335205200_B56","doi-asserted-by":"crossref","first-page":"e103742","DOI":"10.1371\/journal.pone.0103742","article-title":"Evaluation of retinoids for induction of the redundant gene ABCD2 as an alternative treatment option in X-linked adrenoleukodystrophy","volume":"9","author":"Weber","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"2020071622335205200_B57","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/jnc.13562","article-title":"Metformin-induced mitochondrial function and ABCD2 up-regulation in X-linked adrenoleukodystrophy involves AMP-activated protein kinase","volume":"138","author":"Singh","year":"2016","journal-title":"J Neurochem"},{"issue":"1-2","key":"2020071622335205200_B58","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1006\/mgme.2001.3239","article-title":"Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy","volume":"74","author":"McGuinness","year":"2001","journal-title":"Mol Genet Metab"},{"issue":"5","key":"2020071622335205200_B59","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/hmg\/11.5.499","article-title":"Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy","volume":"11","author":"Pujol","year":"2002","journal-title":"Hum Mol Genet"},{"issue":"5954","key":"2020071622335205200_B60","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/158\/5\/1328\/14068790\/en.2016-1842.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/158\/5\/1328\/14068790\/en.2016-1842.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T06:59:34Z","timestamp":1594969174000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/158\/5\/1328\/2996235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,14]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2016-1842","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,5,1]]},"published":{"date-parts":[[2017,2,14]]}}}